TD Cowen analyst Ritu Baral has maintained their bullish stance on ANRO stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors including Alto Neuroscience, Inc.’s promising pipeline and financial stability. The company is advancing several key clinical trials, such as the Phase 2 proof-of-concept study for their ALTO-101 compound targeting cognitive impairment associated with schizophrenia. This study is designed to assess the impact of the compound on EEG markers and cognitive performance, with topline data expected in the second half of 2025.
Additionally, Alto Neuroscience’s financial position is robust, with a cash runway projected to last into 2028, despite reporting a net loss in the second quarter of 2025. The company’s strategic focus on innovative treatments for neurological conditions, coupled with its solid financial foundation, supports the positive outlook and Buy rating given by Ritu Baral.